{"id":"abrocitinib-suspension-f1","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Live vaccines","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Bacillus Calmette-Guérin (BCG) vaccine","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Other vaccines","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Live attenuated influenza vaccine","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Toxoids","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Inactivated vaccines","action":"No action required","effect":"No interaction"},{"drug":"Interferon-alpha","action":"Monitor","effect":"Increased risk of infection"},{"drug":"Interferon-beta","action":"Monitor","effect":"Increased risk of infection"},{"drug":"Interferon-gamma","action":"Monitor","effect":"Increased risk of infection"},{"drug":"TNF-alpha inhibitors","action":"Monitor","effect":"Increased risk of infection"},{"drug":"TNF-beta inhibitors","action":"Monitor","effect":"Increased risk of infection"},{"drug":"TNF-alpha and TNF-beta inhibitors","action":"Monitor","effect":"Increased risk of infection"},{"drug":"Corticosteroids","action":"Monitor","effect":"Increased risk of infection"},{"drug":"Immunosuppressants","action":"Monitor","effect":"Increased risk of infection"},{"drug":"Other immunosuppressants","action":"Monitor","effect":"Increased risk of infection"},{"drug":"Live attenuated influenza vaccine","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Toxoids","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Inactivated vaccines","action":"No action required","effect":"No interaction"}],"commonSideEffects":[],"contraindications":["Do not start CIBINQO if you: - are under 12 years of age\n- intend to use it for a condition for which it was not prescribed - have any kind of infection unless your healthcare provider tells you it is okay - have any signs and symptoms of blood clots - have lymphocyte, neutrophil, red blood cell, or platelet counts that are too low - take medicines that prevent blood clots (antiplatelet medicines), except for low-dose aspirin up to a dose of 81 mg each day during the first 3 months of CIBINQO treatment - are taking certain other medicines\n- are breastfeeding or plan to breastfeed\n- have severe kidney problems - have severe liver problems\n- recently received a live vaccine"],"specialPopulations":{"Pregnancy":"There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to CIBINQO during pregnancy. Pregnant women exposed to CIBINQO and health care providers are encouraged to call 1-877-311-3770. Risk Summary Available data from pregnancies reported in clinical trials with CIBINQO are not sufficient to establish a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal studies, there were no effects on fertility or reproductive performance. However, the effects of CIBINQO on human fertility are not known.","Geriatric use":"No specific studies have been conducted in geriatric patients. However, the pharmacokinetics of CIBINQO in geriatric patients were similar to those in younger adults. The safety and effectiveness of CIBINQO in geriatric patients have not been established.","Paediatric use":"The safety and effectiveness of CIBINQO in pediatric patients 12 years of age and older weighing 25 kg or more have been established. The safety and effectiveness of CIBINQO in pediatric patients under 12 years of age have not been established. The pharmacokinetics of CIBINQO in pediatric patients 12 years of age and older were similar to those in adults. However, the safety and effectiveness of CIBINQO in pediatric patients 12 years of age and older were not evaluated in clinical trials.","Renal impairment":"Avoid use in patients with severe renal impairment or end-stage renal disease. In patients with severe (eGFR <30 mL/min) and moderate (eGFR 30-59 mL/min) renal impairment, the dosage adjustment is not required. However, the safety and effectiveness of CIBINQO in patients with atopic dermatitis with baseline creatinine clearance values less than 40 mL/min were not evaluated.","Hepatic impairment":"Avoid use of CIBINQO in patients with severe (Child Pugh C) hepatic impairment. Dosage adjustment is not required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment. The safety and effectiveness of CIBINQO in patients with severe (Child Pugh C) hepatic impairment have not been studied."}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=abrocitinib-suspension-f1","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:51:36.705600+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:51:42.544643+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:51:36.778213+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=abrocitinib-suspension-f1","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:51:42.865886+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tyrosine-protein kinase JAK1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:51:43.951718+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3655081/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:51:43.620417+00:00"}},"allNames":"abrocitinib suspension f1","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Abrocitinib Suspension F1 is a marketed drug by Pfizer Inc. It targets the JAK1 protein, a key player in inflammation. Abrocitinib Suspension F1 is used to treat moderate to severe atopic dermatitis in adults and children 12 years of age and older. This drug offers clinical differentiation through its high efficacy and rapid onset of action. Commercially, Abrocitinib Suspension F1 has achieved significant revenue of $21.2B. There are no pipeline developments mentioned for this drug.","brandName":"Abrocitinib Suspension F1","ecosystem":[],"isGeneric":true,"mechanism":{"target":"JAK1","novelty":"best-in-class","modality":"small molecule","drugClass":"JAK inhibitor","explanation":"","oneSentence":"","technicalDetail":"Abrocitinib Suspension F1 is a JAK1 inhibitor that works by binding to the JAK1 protein and preventing it from interacting with its substrate. This inhibition of JAK1 leads to a reduction in inflammation and an improvement in symptoms of atopic dermatitis. As a result, Abrocitinib Suspension F1 can provide effective treatment for patients with moderate to severe atopic dermatitis."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:53.638Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"revenueYear":2025,"annualCostUS":"$80,000/yr","annualRevenue":284,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Pfizer (2026-02-03)","currentRevenue":"$21.2B","revenueCurrency":"USD","peakSalesEstimate":"$21.2B","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T10:48:50.281182","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=abrocitinib-suspension-f1","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=abrocitinib-suspension-f1","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:45.368478+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Dupixent (dupilumab)","company":"Sanofi and Regeneron Pharmaceuticals","advantage":"Alternative Janus kinase (JAK) inhibitor for treating atopic dermatitis"},{"name":"Ebglyss (lebrikizumab)","company":"Novartis","advantage":"Alternative interleukin inhibitor for treating atopic dermatitis"},{"name":"Triamcinolone topical","company":"Various","advantage":"Topical corticosteroid for treating atopic dermatitis"},{"name":"Clobetasol topical","company":"Various","advantage":"Topical corticosteroid for treating atopic dermatitis"},{"name":"Tacrolimus topical","company":"Various","advantage":"Topical immunomodulator for treating atopic dermatitis"},{"name":"Dupilumab","company":"Sanofi and Regeneron Pharmaceuticals","advantage":"Alternative interleukin inhibitor for treating atopic dermatitis"},{"name":"Betamethasone topical","company":"Various","advantage":"Topical corticosteroid for treating atopic dermatitis"},{"name":"Adquey","company":"Unknown","advantage":"Unknown"}],"genericName":"abrocitinib-suspension-f1","indications":{"approved":[{"name":"Moderate to severe atopic dermatitis in adults","regulator":"FDA"},{"name":"Moderate to severe atopic dermatitis in children 12 years of age and older","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04903093","phase":"PHASE1","title":"A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-06-04","conditions":"Healthy Volunteers","enrollment":19}],"_emaApprovals":[{"date":"","name":"Abrocitinib Suspension F1","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL3655081","moleculeType":"Small molecule","molecularWeight":"323.42"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL3655081"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-04-01 09:48:50.313664+00","biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:45.368478+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}